Results 21 to 30 of about 382,334 (303)

Inter-α-Inhibitor Impairs TSG-6-Induced Hyaluronan Cross-Linking [PDF]

, 2013
Under inflammatory conditions and in the matrix of the cumulus-oocyte complex (COC), the polysaccharide hyaluronan (HA) becomes decorated covalently with heavy chains (HCs) of the serum glycoprotein inter-α-inhibitor (IαI).
Briggs, David C., Richter, Ralf P., Day, Anthony J., Ralf P. Richter, Baranova, Natalia, Viranga Tilakaratna, Day, Anthony J.; id_orcid, David C. Briggs, Natalia S. Baranova, Tilakaratna, Viranga, Enghild, Jan J., Caroline M. Milner, Baranova, Natalia S., Jan J. Enghild, Milner, Caroline M., Foulcer, Simon J., Simon J. Foulcer, Anthony J. Day   +17 more
core   +1 more source

The role of Interleukin 6 inhibitors in therapy of severe COVID-19

Biomedicine & Pharmacotherapy, 2020
Cytokine storm syndrome (CSS) is a severe complication of inflammatory immune diseases or treatment of malignancies; it may also appear during the progression of COVID-19. CSS is caused by dysregulation of the synthesis of cytokines, including pro-inflammatory, regulatory, and anti-inflammatory cytokines and chemokines, leading to pathologic activation
Nasonov, E., Samsonov, M.
openaire   +3 more sources

A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease [PDF]

Clinical and Experimental Immunology, 2005
SummaryThe presence and the role of soluble gp130, the soluble form of a component of the interleukin (IL)-6 receptor complex, were investigated in inflammatory bowel disease. The serum concentrations of soluble gp130 were increased in ulcerative colitis (active disease, median, 93·5 ng/ml; interquartile range, 26–125 ng/ml; inactive disease, 81 ng/ml,
K, Mitsuyama, N, Tomiyasu, A, Suzuki, K, Takaki, H, Takedatsu, J, Masuda, H, Yamasaki, S, Matsumoto, O, Tsuruta, A, Toyonaga, M, Sata   +10 more
openaire   +2 more sources

Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma

Frontiers in Oncology, 2023
PurposeAnlotinib, a tyrosine kinase inhibitor (TKI) has been in clinical application to inhibit malignant cell growth and lung metastasis in osteosarcoma (OS). However, a variety of drug resistance phenomena have been observed in the treatment. We aim to
Jiuhui Xu, Jiuhui Xu, Chenglong Chen, Chenglong Chen, Kunkun Sun, Qianyu Shi, Qianyu Shi, Boyang Wang, Boyang Wang, Yi Huang, Yi Huang, Tingting Ren, Tingting Ren, Xiaodong Tang, Xiaodong Tang   +14 more
doaj   +1 more source

AB0470 EXPERIENCE WITH THE USE OF INTERLEUKIN 6 INHIBITOR IN SEVERE ANKYLOSING SPONDYLITIS [PDF]

Annals of the Rheumatic Diseases, 2021
Background: Inhibitors of interleukin 6 (IL6) have been found to be ineffective in ankylosing spondylitis (AS) based on the results of randomized clinical trials (RCTs) on tocilizumab (TCZ) and sarilimumab [1, 2]. However, there is evidence that IL6 is actively involved in the pathogenesis of the disease [3].
D. Rumiantceva, E. Agafonova, M. Urumova, S. Erdes   +3 more
openaire   +1 more source

Ginkgo biloba extract reduces high-glucose-induced endothelial adhesion by inhibiting the redox-dependent interleukin-6 pathways

Cardiovascular Diabetology, 2012
Background Chronic elevation of glucose level activates vascular inflammation and increases endothelial adhesiveness to monocytes, an early sign of atherogenesis.
Chen Jia-Shiong, Chen Yung-Hsiang, Huang Po-Hsun, Tsai Hsiao-Ya, Chen Yuh-Lien, Lin Shing-Jong, Chen Jaw-Wen   +6 more
doaj   +1 more source

Atypical course of COVID-19 in patient with Bruton agammaglobulinemia

Journal of Infection in Developing Countries, 2020
We present atypical course of the novel coronavirus disease (COVID-19) in 34-year man with Bruton agammaglobulinemia. The patient was successfully treated by a combination of available drugs, including convalescent plasma and interleukin-6 (IL-6 ...
Ivana Milošević, Jaroslava Jovanović, Olja Stevanovic   +2 more
doaj   +1 more source

The benefits and prospects of interleukin-6 inhibitor on systemic sclerosis [PDF]

Modern Rheumatology, 2019
Systemic sclerosis (SSc) is a connective tissue disease, the pathogenesis of which is thought to involve interleukin-6 (IL-6), an inflammatory cytokine. This is based on findings of its concentration in patient serum, the results of an IL-6 suppression experiment in an animal model, and the results of a pilot study using IL-6 receptor antibody. However,
openaire   +2 more sources

Suppression of signal transducer and activator of transcription 3-dependent B lymphocyte terminal differentiation by BCL-6 [PDF]

, 2000
Lymphocytes usually differentiate into effector cells within days after antigen exposure, except in germinal centers where terminal differentiation is delayed while somatic hypermutation creates high-affinity antibody mutants. Here we investigate whether
Peakman, LJ, Rajko Reljic (406091), Rajko Reljic, Reljic, R, Fearon, DT, Simon D. Wagner, Luke J. Peakman, Luke J. Peakman (7768292), Fearon, D T, Douglas T. Fearon, Wagner, S D, Wagner, SD, Simon D. Wagner (7633943), Douglas T. Fearon (7768295), Peakman, L J   +14 more
core   +1 more source

HSP70 inhibitors upregulate prostaglandin E1-induced synthesis of interleukin-6 in osteoblasts

PLOS ONE, 2022
Interleukin-6 (IL-6) is a pro-inflammatory and bone-resorptive cytokine that also regulates bone formation. We previously showed that prostaglandin E1 (PGE1) induces the synthesis of IL-6 by activating p44/p42 mitogen-activated protein kinase (MAPK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 MAPK in osteoblast-like ...
Gen Kuroyanagi, Junko Tachi, Kazuhiko Fujita, Tetsu Kawabata, Go Sakai, Daiki Nakashima, Woo Kim, Kumiko Tanabe, Rie Matsushima-Nishiwaki, Takanobu Otsuka, Hiroki Iida, Osamu Kozawa, Haruhiko Tokuda   +12 more
openaire   +3 more sources